The FDA's own regulations likewise require that the labeling proposed for a generic drug “must be the same as the labeling approved for the reference listed drug ...” with certain limited exceptions to account for the fact that the generic drug is produced by a different manufacturer. 21 C.F.R. § 314.94(a)(8)(iv)(1999) (emphasis added). Although FDA received comments proposing that it permit differences in labeling for various reasons, FDA rejected these proposals, stating:Except for labeling differences due to exclusivity or a patent and differences under section 505(j)(2)(v) of the act, the ANDA product's labeling must be the same as the listed drug product's labeling because the listed drug product is the basis for ANDA approval. Consistent labeling will assure physicians, health professionals, and consumers that a generic drug is as safe and effective as its brand name counterpart.